癌症免疫疗法已被证明在多种类型的癌症中具有临床疗效。淋巴细胞功能相关抗原1 (LFA-1)是一种整合素家族的黏附分子，主要表达在αβT细胞上。LFA-1与肿瘤免疫应答相关，但其具体机制仍未知。本研究采用LFA-1基因敲除（LFA-1-/-）小鼠携带皮下肿瘤和Apc Min/+;LFA-1-/-小鼠构建两种肿瘤模型，确认LFA-1敲除会抑制肿瘤生长。此外，研究还表明，在LFA-1-/-小鼠的脾脏、血液和肠系膜淋巴结中，调节性T细胞（Treg细胞）的数量减少，并且在Apc Min/+;LFA-1-/-小鼠的肠系膜淋巴结中，Treg细胞数量也减少，相比之下，Apc Min/+小鼠的Treg细胞数量较多。给予LFA-1抑制剂(BIRT377)的皮下肿瘤携带LFA-1+/+小鼠研究结果显示，肿瘤生长被抑制，Treg细胞数量减少。TIMER肿瘤数据库分析显示，LFA-1表达与Treg细胞和TNM分期呈正相关。综上所述，这表明LFA-1基因敲除可以抑制肿瘤生长并与Treg细胞相关。LFA-1可能是癌症免疫疗法的潜在靶点之一。视频摘要。© 2023. BioMed Central Ltd., 集Springer Nature之一。

Cancer immunotherapy has been proven to be clinically effective in multiple types of cancers. Lymphocyte function-associated antigen 1 (LFA-1), a member of the integrin family of adhesion molecules, is expressed mainly on αβ T cells. LFA-1 is associated with tumor immune responses, but its exact mechanism remains unknown. Here, two kinds of mice tumor model of LFA-1 knockout (LFA-1-/-) mice bearing subcutaneous tumor and Apc Min/+;LFA-1-/- mice were used to confirm that LFA-1 knockout resulted in inhibition of tumor growth. Furthermore, it also demonstrated that the numbers of regulatory T cells (Treg cells) in the spleen, blood, mesenteric lymph nodes were decreased in LFA-1-/- mice, and the numbers of Treg cells in mesenteric lymph nodes were also decreased in Apc Min/+;LFA-1-/- mice compared with Apc Min/+ mice. LFA-1 inhibitor (BIRT377) was administered to subcutaneous tumor-bearing LFA-1+/+ mice, and the results showed that the tumor growth was inhibited and the number of Treg cells was reduced. The analysis of TIMER tumor database indicated that LFA-1 expression is positively associated with Treg cells and TNM stage. Conclusively, this suggests that LFA-1 knockout would inhibit tumor growth and is correlated with Treg cells. LFA-1 may be one potential target for cancer immunotherapy. Video Abstract.© 2023. BioMed Central Ltd., part of Springer Nature.